Version May 2024
Genital or perianal warts: Topical: Gel or solution: Apply twice daily (morning and evening) for 3 days, then withhold use for 4 days; this cycle may be repeated up to 4 times until there is no visible wart tissue; maximum dose: 0.5 g (gel) or 0.5 mL (solution) daily (or ≤10 cm2 of wart tissue) (Ref). Note: Discontinue after 4 treatment cycles if incomplete response and consider alternative treatment; do not repeat use.
Molluscum contagiosum (off-label use): Topical: Gel or solution: Apply twice daily (morning and evening) for 3 consecutive days, then withhold use for 4 consecutive days; this cycle may be repeated up to 4 times until lesion resolution (Ref).
There are no dosage adjustments provided in the manufacturer's labeling.
There are no dosage adjustments provided in the manufacturer's labeling.
Refer to adult dosing.
The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.
Gel, topical:
>10%:
Central nervous system: Localized burning (12% to 37%), local pain (12% to 24%)
Dermatologic: Skin erosion (9% to 27%)
Hematologic & oncologic: Local hemorrhage (<1% to 19%)
Local: Local inflammation (9% to 32%), local pruritus (8% to 32%)
1% to 10%:
Central nervous system: Headache (7%)
Dermatologic: Stinging of the skin (7%), erythema (5%)
<1%, postmarketing, and/or case reports: Crusted skin, dermal ulcer, desquamation, edema, skin blister, skin discoloration, skin fissure, skin rash, skin tenderness, tingling of skin, xeroderma
Solution, topical:
>10%:
Central nervous system: Localized burning (female 78%; male 64%), local pain (female 72%; male 50%)
Dermatologic: Skin erosion (67%)
Local: Local inflammation (male 71%; female 63%), local pruritus (female 65%; male 50%)
<1%, postmarketing, and/or case reports: Body odor, dermal ulcer, dizziness, hematuria, insomnia, local hemorrhage, localized edema, localized vesiculation, pain, skin tenderness, tingling of skin, vomiting, xeroderma
Hypersensitivity or intolerance to any component of the formulation.
Canadian labeling: Additional contraindications (not in the US labeling): Concurrent use with other podophyllin-containing products; patients with open wounds or inflamed or bleeding lesions; children <12 years of age; pregnancy; breastfeeding.
Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.
Concerns related to adverse effects:
• Skin reactions: Most skin reactions are mild to moderate and did not increase during the treatment period, however severe skin reactions can occur. Severe reactions are most frequent within the first two weeks of treatment.
Dosage form specific issues:
• Topical gel and solution: Flammable; keep away from fire or flame.
Other warnings/precautions:
• Appropriate use: For cutaneous use only; avoid contact with eyes. If product comes in contact with the eyes, flush with water and seek medical attention. Not intended for treatment of mucous membrane warts.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Gel, External:
Condylox: 0.5% (3.5 g)
Generic: 0.5% (3.5 g)
Solution, External:
Generic: 0.5% (3.5 mL)
Yes
Gel (Condylox External)
0.5% (per gram): $217.15
Gel (Podofilox External)
0.5% (per gram): $195.43
Solution (Podofilox External)
0.5% (per mL): $30.90
Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.
Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product
Solution, External:
Condyline: 0.5% ([DSC]) [contains alcohol, usp]
Topical: For external use only. Do not apply to mucous membrane warts. Wash hands before and after application. Apply to warts using either the applicator supplied with the drug (gel, solution) or with finger (gel only) while minimizing exposure to surrounding normal tissue. Dispose applicator tip carefully after use. Allow the gel or solution to dry before allowing return of opposing skin surfaces to their normal positions; wash hands after application.
Genital warts: Treatment of external genital warts
Perianal warts: Treatment of perianal warts (gel only)
Molluscum contagiosum
None known.
There are no known significant interactions.
Podofilox should not be used during pregnancy (CDC [Workowski 2021]).
It is not known if podofilox is present in breast milk.
Due to the potential for adverse reactions in the breastfed infant, the manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug, considering the importance of the treatment to the mother.
Treated areas for adequate healing; tolerability of treatment
Exact mechanism of action is unknown; causes necrosis of visible wart tissue
Absorption: No detectable serum levels
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟
